Swedish Orphan Biovitrum
sobi.comTotal trials
76
Active
11
Phase 3
19
Total enrollment
10,490
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 6 of 6 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Efanesoctocog alfa | — | — | — | 5 | |||
| Anakinra | — | — | — | 7 | |||
| Pacritinib | — | — | — | — | 2 | ||
| Physician's Choice medications | — | — | — | — | — | 1 | |
| Pegcetacoplan | — | — | — | 3 | |||
| ELOCTA | — | — | — | — | — | 2 |
Next readouts
- 2025-12-10
- 2026-05-22
- 2026-05-30
- 2026-07
- 2026-08-15
- 2026-10-05
- 2026-11-17
- 2026-12-30
- 2027-03
- 2027-08-30
Top conditions
- Hemophilia A8
- Haemophilia B4
- Still's Disease, Adult-Onset4
- Hereditary Tyrosinemia, Type I4
- Macrophage Activation Syndrome3
- Leukemia3
- Haemophilia A3
- Hemophilia B3
Frequently asked questions about Swedish Orphan Biovitrum
- How many clinical trials does Swedish Orphan Biovitrum have on ClinicalTrials.gov?
- Swedish Orphan Biovitrum is listed as the lead sponsor on 76 clinical trials in ClinicalTrials.gov, 11 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Swedish Orphan Biovitrum's trials are in Phase 3?
- 19 of Swedish Orphan Biovitrum's trials are in Phase 3, spread across 6 active drug programs.
- What therapeutic areas does Swedish Orphan Biovitrum focus on?
- Swedish Orphan Biovitrum's most-studied conditions on ClinicalTrials.gov are Hemophilia A, Haemophilia B, Still's Disease, Adult-Onset, Hereditary Tyrosinemia, Type I, Macrophage Activation Syndrome.
- When are Swedish Orphan Biovitrum's next clinical trial readouts?
- Swedish Orphan Biovitrum has 10 upcoming primary-completion readouts tracked here; the soonest is “A Study of Anakinra in Japanese Patients With Still's Disease (SJIA and AOSD)”, expected around 2025-12-10.